accountcompany focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to InterMune To Release First Quarter Financial Results On April 28
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account